Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations.

Area of Science:

• Bioconjugation Chemistry
• Oncology Therapeutics
• Pharmaceutical Development

Background:

• Antibody-drug conjugates (ADCs) are a key advancement in targeted cancer therapy.
• Overcoming drug resistance and enhancing therapeutic efficacy remain critical challenges in cancer treatment.

Purpose of the Study:

• To review methodologies for site-specific dual-payload ADC development.
• To analyze the impact of conjugation techniques on ADC properties and manufacturability.
• To compare dual-payload ADCs with existing therapeutic strategies.

Main Methods:

• Examination of multi-functional linkers for dual conjugation.
• Evaluation of canonical and non-canonical amino acid incorporation.
• Assessment of enzyme-mediated conjugation strategies.
• Analysis of drug-to-antibody ratio and payload ratio control.

Main Results:

• Site-specific conjugation enables precise control over payload attachment and homogeneity.
• Different methods impact drug-to-antibody ratios, payload ratios, and process complexity.
• Dual-payload ADCs show potential advantages over single-payload ADCs and traditional chemotherapy.

Conclusions:

• Site-specific dual-payload ADCs represent a significant advancement in targeted cancer therapy.
• Further research into conjugation techniques is crucial for optimizing dual-payload ADC development.
• Dual-payload ADCs hold promise for overcoming resistance and improving patient outcomes.